IMVT - Immunovant, Inc.

26.71
-1.040   -3.894%

Share volume: 830,413
Last Updated: 03-03-2026
Pharmaceutical Products/Biological Products, Except Diagnostic Substances: 0.31%

PREVIOUS CLOSE
CHG
CHG%
$27.75
-1.04
-0.04%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
21%
Profitability 25%
Dept financing 4%
Liquidity 50%
Performance 15%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-3.68%
1 Month
6.20%
3 Months
16.59%
6 Months
65.69%
1 Year
44.46%
2 Year
-23.11%
Key data
Stock price
$26.71
P/E Ratio 
0.00
DAY RANGE
$26.30 - $27.35
EPS 
-$2.68
52 WEEK RANGE
$12.72 - $29.25
52 WEEK CHANGE
$37.54
MARKET CAP 
4.456 B
YIELD 
N/A
SHARES OUTSTANDING 
203.532 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
08-05-2025
BETA 
0.40
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$1,101,264
AVERAGE 30 VOLUME 
$1,339,349
Company detail
CEO: Peter Salzmann
Region: US
Website: immunovant.com
Employees: 120
IPO year: 2019
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. IMVT-1401 is in Phase IIa clinical trials for the. treatment of myasthenia gravis and thyroid eye disease. The company is headquartered in New York, New York.

Recent news